CA2363496A1 - Expression differentielle de produits geniques d'organites - Google Patents

Expression differentielle de produits geniques d'organites Download PDF

Info

Publication number
CA2363496A1
CA2363496A1 CA002363496A CA2363496A CA2363496A1 CA 2363496 A1 CA2363496 A1 CA 2363496A1 CA 002363496 A CA002363496 A CA 002363496A CA 2363496 A CA2363496 A CA 2363496A CA 2363496 A1 CA2363496 A1 CA 2363496A1
Authority
CA
Canada
Prior art keywords
cells
cell
state
interest
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002363496A
Other languages
English (en)
Inventor
Corrina Herrnstadt
Scott W. Miller
Robert E. Davis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Migenix Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2363496A1 publication Critical patent/CA2363496A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1072—Differential gene expression library synthesis, e.g. subtracted libraries, differential screening
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention a trait à des compositions et des méthodes d'identification de facteurs, y compris des facteurs d'organites, qui sont exprimés de manière différentielle, lorsque des cellules dans des états différents, tels que des états métaboliques, respiratoires, malades ou apoptiques, sont comparées. Selon des modes de réalisation préférés, l'invention concerne des cellules ( rho <0>) dépourvues d'ADN de mitonchondrie et des cellules hybrides cytoplasmiques (cybrides), telles que les cellules cybrides mitochondriales. On envisage l'utilisation de cette invention pour identifier l'expression spécifique d'espèces de facteurs d'organites tels que l'organite associé à des macromolécules. L'invention concerne également des exemples de facteurs d'organites qui sont exprimés de manière différentielle dans une maladie associée à l'organite, ainsi qu'une variété de gènes humains qui sont exprimés de manière différentielle dans la maladie d'Alzheimer.
CA002363496A 1999-03-16 2000-03-16 Expression differentielle de produits geniques d'organites Abandoned CA2363496A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12467399P 1999-03-16 1999-03-16
US60/124,673 1999-03-16
US52697700A 2000-03-15 2000-03-15
US09/526,977 2000-03-15
PCT/US2000/007311 WO2000055323A1 (fr) 1999-03-16 2000-03-16 Expression differentielle de produits geniques d'organites

Publications (1)

Publication Number Publication Date
CA2363496A1 true CA2363496A1 (fr) 2000-09-21

Family

ID=26822840

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002363496A Abandoned CA2363496A1 (fr) 1999-03-16 2000-03-16 Expression differentielle de produits geniques d'organites

Country Status (5)

Country Link
EP (1) EP1161534A1 (fr)
JP (1) JP2003524397A (fr)
AU (1) AU3900600A (fr)
CA (1) CA2363496A1 (fr)
WO (1) WO2000055323A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020220A2 (fr) * 2001-08-30 2003-03-13 Emory University Reseaux d'expression de biologie mitochondriale
WO2005074988A1 (fr) * 2004-02-06 2005-08-18 Locomogene, Inc. Inducteur de differenciation de cellule nerveuse

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0743989B1 (fr) * 1994-02-14 2007-03-21 Smithkline Beecham Corporation Procédé d'identifcation des genes exprimés differentes
CN1150433A (zh) * 1994-03-30 1997-05-21 米托科公司 线粒体缺陷相关疾病的诊断，治疗以及细胞和动物模型
US5840493A (en) * 1994-03-30 1998-11-24 Mitokor Mitochondrial DNA mutations that segregate with late onset diabetes mellitus
CA2247246A1 (fr) * 1996-02-16 1997-08-21 Millennium Pharmaceuticals, Inc. Compositions et procedes de traitement et de diagnostic des maladies cardio-vasculaires
IL129872A0 (en) * 1996-11-12 2000-02-29 Qbi Entpr Ltd Method for identifying translationally regulated genes

Also Published As

Publication number Publication date
WO2000055323A1 (fr) 2000-09-21
WO2000055323A9 (fr) 2001-11-15
EP1161534A1 (fr) 2001-12-12
AU3900600A (en) 2000-10-04
JP2003524397A (ja) 2003-08-19

Similar Documents

Publication Publication Date Title
Kantheti et al. Mutation in AP-3 δ in the mocha mouse links endosomal transport to storage deficiency in platelets, melanosomes, and synaptic vesicles
Sato et al. The AtVAM3 encodes a syntaxin-related molecule implicated in the vacuolar assembly in Arabidopsis thaliana
Vassalli et al. Minigenes impart odorant receptor-specific axon guidance in the olfactory bulb
Chen et al. Transcriptional enhancer factor 1 disruption by a retroviral gene trap leads to heart defects and embryonic lethality in mice.
EP0656954B1 (fr) Procede de production de genes, produits de transcription et proteines marques
AU2017293773A1 (en) CRISPR/Cas9-based compositions and methods for treating retinal degenerations
KR20200006054A (ko) 신규 타입 vi crispr 오르소로그 및 시스템
Rudner et al. Mutations in the small subunit of the Drosophila U2AF splicing factor cause lethality and developmental defects.
KR20210077732A (ko) Nme2cas9-데아미나아제 융합 단백질에 의한 프로그램 가능한 dna 염기 편집
Mayrhofer et al. Pheromones and pheromone receptors are required for proper sexual development in the homothallic ascomycete Sordaria macrospora
US20040072739A1 (en) Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes
Lee et al. Gene knockouts reveal separate functions for two cytoplasmic dyneins in Tetrahymena thermophila
JP2023113657A (ja) Ｂ４ｇａｌｔ１バリアント及びその使用
Corydon et al. Human and mouse mitochondrial orthologs of bacterial ClpX
CA2363496A1 (fr) Expression differentielle de produits geniques d&#39;organites
US20170355956A1 (en) Compositions for increasing survival of motor neuron protein (smn) levels in target cells and methods of use thereof for the treatment of spinal muscular atrophy
EP0927046A1 (fr) Regulateur de la degradation de l&#39;arn chez les mammiferes induite par des transcrits non-sens
CA2390646A1 (fr) Compositions et methodes pour reguler l&#39;inhibiteur endogene de l&#39;atp-synthase, et pour le traitement du diabete
US20210284979A1 (en) Methods and compositions for genetically manipulating genes and cells
JP2003235575A (ja) 哺乳動物において機能的なトランスポゾン
US20030026781A1 (en) Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes
Otten et al. ACRC/GCNA is an essential protease for the repair of DNA-protein crosslinks during vertebrate development
US20220316008A1 (en) Compositions comprising rare genetic sequence variants associated with pulmonary function and methods of use thereof for diagnosis and treatment of asthma in african american patients
Degl'Innocenti et al. ACYP1 gene possesses two alternative splicing forms that induce apoptosis
Ye et al. Low grain weight, a new allele of BRITTLE CULM12, affects grain size through regulating GW7 expression in rice

Legal Events

Date Code Title Description
FZDE Dead